Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$0.91 USD
-0.01 (-0.90%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $0.91 0.00 (0.39%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MCRB 0.91 -0.01(-0.90%)
Will MCRB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MCRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MCRB
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
MCRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for MCRB
Largest borrow rate increases among liquid names
Strong Buy Recommendation: Seres Therapeutics’ Enhanced Financial Position and Promising Clinical Prospects
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
Seres Therapeutics Announces Signing of VOWST? Asset Purchase Agreement with Nestle Health Science
Seres Therapeutics Announces Asset Purchase Agreement with Nestlé